期刊文献+

慢性肾衰竭患者血浆sCD40和sCD40L的变化 被引量:2

The changes of plasma soluble CD40 and soluble CD40L in patients with chronic renal failure and their clinical significance
原文传递
导出
摘要 目的探讨慢性肾衰竭(CRF)患者血浆中可溶性CIMO(sCD40)和可溶性CD40配体(sCD40L)的变化以及在肾损伤和免疫异常中的可能作用。方法选择2006年9月至12月首都医科大学附属北京同仁医院肾内科收治的慢性肾衰竭未透析患者(CRF组)30例,血液透析中心维持性血液透析3个月以上的尿毒症患者(HD组)30例,与患者年龄、性别相匹配的健康正常对照组20例。采用酶联免疫吸附法(ELISA)测定血浆sCD40和sCD40L的水平,并进行相关因素分析,观察血液透析对sCD40和sCD40L的影响。用方差分析和Pearson相关性分析进行统计学分析。结果(1)CRF组和HD组sCD40水平均明显高于对照组(P〈0.01),HD组sCD40水平较CRF组升高(P〈0.01);(2)CRF组和HD组sCD40L水平均明显高于对照组(P〈0.01),HD组sCD40L水平较CRF组轻度升高,但无显著差异(P〉0.05);(3)CRF组sCD40水平与血肌酐(Scr)和C-反应蛋白(CRP)之间成正相关(r=0.637,P〈0.01;r=0.551,P〈0.05),sCD40L水平与Ser和CRP之间也存在相关性(r=0.553,P〈0.05;r=0.686,P〈0.01),sCD40、sCD40L水平与血压、血红蛋白(Hb)、血小板(PLT)、白细胞(WBC)、血白蛋白(AIb)、血糖(Glu)、尿素氮(Bun)及血脂等指标之间无相关性(P〉0.05)。血液透析组sCD40、sCD40L与上述指标之间无相关性,与透析病程和透析充分性(Kt/V)之间也无相关性(P〉0.05);(4)一次血液透析过程,HD后sCD40水平较HD前略有升高,差异无统计学意义(P〉0.05),HD后sCD40L水平较HD前下降,差异具有统计学意义(P〈0.01)。结论CRF患者血浆中sCD40和sCD40L水平升高,HD患者更明显,有可能参与CRF患者肾损伤和免疫异常。 Objective To investigate the changes of plasma soluble CD40 (sCD40) and soluble CD40L (sCD40L) in patients with chronic renal failure(CRF) and their potiential mechanisms in renal injury and immunodeficiency. Method From September to December 2006, 30 CRF patients without hemodialysis (CRF group) in department of Nephrology and 30 uremic patients receiving maintenance hemodialysis for more than 3 months (HD group) in dialysis center in Beijing TongRen Hospital of Capital Medical University, were enrolled in this study. The normal control group consisted of 20 healthy volunteers who matched with study subjects for age and gender. The levels of plasma sCD40 and sCD40L were measured by the method of enzyme linked immunosorbent assay (ELISA). The relationship between sCD40, sCD40L and related factors were analyzed, and the influence of hemodialysis on sCD40 and sCD40L were observed. ANOVA and Pearson correlation analysis were used in statistical analysis. Results ( 1 ) The sCD40 levels in CRF group and HD group were significantly higher than those in control group ( P 〈 0.01 ). The sCD40 levels in HD group were also higher than those in CRF group ( P 〈 0.01). (2) The sCD40L levels in CRF group and HD group were significantly higher than those in control group ( P 〈 0.01 ). The sCD40L levels in HD group were slightly higher than those in CRF group, but without significant diffrerence ( P 〉 0.05). (3) In CRF group, the sCD40 levels correlated positively with serum creatinine (Scr) and C-reactive protein(CRP) (r = 0. 637, P 〈 0.01, r = 0. 551, P 〈 0.05). The correlations between sCD40L and Scr and CRP were 'also seen ( r = 0.553, P 〈 0.05, r = 0. 686, P 〈 0.01 ), whereas the correlation with blood pressure, hemoglobin (Hb), platelet (PLT), white blood cell ( WBC ), serum albumin (Alb), glucose (Glu), blood urea nitrogen(Bun) and serum lipid was no seen (P 〉 0.05). In HD group, there were no correlations between sCD40, sCD40L and above parameters ( P 〉 0.05), there were also no correlations between sCIMO, sCD40L and duration of the treatment by dialysis and dialysis adequacy(Kt/V) (P 〉 0.05). (4)Mter one HD session, the post-HD levels of sCD40 were slightly higher than pre-HD levels, but without statistical difference ( P 〉 0.05). The post-HD levels of sCD40L were obviously lower than pre-HD levels, with significant difference ( P 〈 0.01 ). Conclusions The levels of sCD40 and sCD40L in CRF patients, particularly in HD patients, were significantly higher than those of controls, which may participate in pathogenesis of renal injury and immunodeficiency.
出处 《中华急诊医学杂志》 CAS CSCD 2008年第9期969-973,共5页 Chinese Journal of Emergency Medicine
关键词 肾衰竭 慢性 血液透析 可溶性CD40 可溶性CD40配体 CD40/CD40配体 Renal failure Chronic Hemodialysis Soluble CD40 Soluble CD40 ligmM CD40/CD40 ligand
  • 相关文献

参考文献12

  • 1Yellin MJ,D'Agati V,Parkinson G,et al.Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides[J].Arthritis Rheum,1997,40(1):124-134.
  • 2Van K, Gerritsma JS, Paape ME. Possible role of CD40-CD40L in the regulation of interstitial infiltration in the kidney[J]. Kidney Int, 1997, 51(3) :711-721.
  • 3VanKooten C, Banchereau J. CD40-CD40 ligand[J]. Leukoc Biol, 2000( 1 ),67 : 2-17.
  • 4Peng DQ, Zhao SP, Li VF , et al . Elevated soluble CD40 ligand is related to theendothelial adhesion molecules in patients with acute coronary. syndrome[J]. Clinica Chimica Acta, 2002,319( 1 ) : 19-26.
  • 5李艳春,廖常志,王莉,何强,王芳,杨秀川.血液透析患者血浆中可溶性CD40及CD4+T细胞上CD154水平的变化[J].中国血液净化,2003,2(7):363-365. 被引量:3
  • 6Kairaitis L, Wang Y, Zheng L, et al. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease[J]. Kidney Int, 2005,64(4) : 1265-1272.
  • 7lin R, Liu J, Gan W , et al. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells [ J ]. Biol Pharm Bull, 2004, 27 (10) : 1537- 1543.
  • 8Viallard JF, Anne S, Bruno G, et al. Increased soluble and platalet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis[ J]. Blood, 2002,99(7) :2612-2614.
  • 9Goules A, Tzioufas AG, Manousakis MN, et al. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases[J]. J Autoimmun, 2006, 26(3) : 165-171.
  • 10Contin C, Pitard V, Delmas Y, et al. Potential role of soluble CD40 in the immune response impairment of uraemic patients [ J ]. Immunol, 2003,110( 1 ) : 131-140.

二级参考文献9

  • 1[1]Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv Immunol, 1996, 63: 43-78
  • 2[2]Kooten CV, Gerritsma JSJ, Paape ME, et al. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int, 1997, 51: 711-721
  • 3[3]Kooten CV, Gaillard C, Galizzi JP, et al. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release o f soluble CD40. Eur J Immunol, 1994, 24: 707-792
  • 4[4]Yellin MJ, Sinning J, Covey LR, et al. T lymphocyte T cell-B cell-activating m olecule/CD40L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Lmmu nol, 1994, 153: 666-674
  • 5[5]Schwabe RF, Engelmann H, Hess S, et al. Soluble CD40 in the serum of health do nors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Lmmunol, 1999, 117: 153-158
  • 6[6]Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis. Kidney Int, 1993, 43: 878-884
  • 7[7]Bjorck P, Braesch As, Paulie S. Antibodies to distinct epitopes on the CD40 mo lecule co-operate in stimulation and can be used for the detection of soluble CD 40. Immunology, 1994, 83: 430-437
  • 8[8]Grewal IQ, Flavel RA. CD40-CD154 in cell-mediated immunity. Ann Rev Immunol, 1998, 16: 111-135
  • 9[9]Yellin Mj, Dagati V, Parkinson G, et al. Immunohistologic analysis of renal CD 40 and CD40L expression in lupus nephritis and other glomerulonephritis. Arthrit is Rheum, 1997, 40: 124-134

共引文献2

同被引文献27

  • 1Yellin MJ,D, Agati V, Parfdnson G, et al. Immunohistologicanalysis of renal CD^ and CD40L expression in lupus nephritisand other glomerulonephritides [ J]. Arthritis Rheum, 1997,40: 124-134.
  • 2Elgueta R, Benson MJ, deVries VC, et al. Molecularmechanism and function of CD40/CD40 L engagement in theimmune system [J]. Immunol Rev, 2009 , 229: 152-172.
  • 3Kawai M, Masuda A, Kuwana M. A CD^-CD^ interactionin tissue fibrosis [j]. Arthritis Rheum, 2008 , 58 : 3562-3573.
  • 4Takashi K,Ryan S. Distinct T cell/renal tubular epithelialcell interactions define differetial chemokine production :implication for tubular interstitial injury in chronicglomerulonephritides [J]. J Immunol, 2000, 164: 3323-3329.
  • 52ieng G, War^ Y, Mahajan D, et al. IKe role cf tubulointerstitialinflammation [j]. Kidney Int Suppl, 2005 , 94: S96-100.
  • 6Takaharu T,Takashi K,Hidekazu I,et al. Human plateletsstimulate mesangial cells to produce monocyte chemoattractantprotein-1 via the CD^/CD^ ligand pathway and may amplifyglomerular injury [ J ]. J Am Soc Nephrol, 2002,13:2488-2496.
  • 7Oxer DS, Godoy LC, Borba E,et al. PPARy expression isincreased in systemic lupus erythematosus patients andrepresses CD^/CD^L signaling pathway [J] ? Lupus, 2011,20: 575-587.
  • 8Kuroiwa T,Schlimgen R, Illei GG. Monocyte response toThl stimulation and effector function toward human messangialcells are not impaired in patients with lupus nephritis [ j].Clin Immunol, 2003, 106 : 65-72.
  • 9Ciferskd H, Hor6k P, Hennanova Z, et al. The levels ofsCI>3o and of sCD^L in a group of patients with systemic lupuserythematodes and their diagnostic value [ J ]. ClinRheumatol, 2007 , 26 : 723-728.
  • 10Mohan C,Shi Y,Laman JD, et al. Interaction between CD40and its ligand qp39 in the development of murine lupusnephritis [j]. J Immunol, 1995, 154: 1470-1480.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部